$CDAK News
Last published 3y ago
- 3y agoCDAKCodiak BioSciences to Pursue Asset Sale through Voluntary Chapter 11 ProcessGlobeNewswireCAMBRIDGE, Mass., March 27, 2023 (GLOBE NEWSWIRE) -- Codiak BioSciences, Inc. (NASDAQ:CDAK), a clinical-stage biopharmaceutical company pioneering the development of exosome-based therapeutics as a new class of
- 3y agoCDAKCodiak BioSciences to Participate 5th Annual Evercore ISI HealthCONx ConferenceGlobeNewswireCAMBRIDGE, Mass., Nov. 28, 2022 (GLOBE NEWSWIRE) -- Codiak BioSciences, Inc. (NASDAQ:CDAK), a clinical-stage biopharmaceutical company pioneering the development of exosome-based therapeutics as a new class of
- 4y agoCDAKCodiak Presents Preclinical Data on exoASO™-STAT6 and exoASO™-C/EBPβ Programs at the Society for Immunotherapy of Cancer (SITC) 2022 Annual MeetingGlobeNewswire– exoASO-STAT6 demonstrated durable pharmacokinetic/pharmacodynamic profile in preclinical models; biomarkers with clinical translational potential identified, providing a rationale for selecting cancer subtypes for
- 4y agoCDAKCodiak BioSciences Reports Third Quarter 2022 Financial Results and Operational ProgressGlobeNewswire– Patient enrollment continuing in Phase 1 clinical trial of exoASO™-STAT6 in patients with advanced hepatocellular carcinoma; preliminary data anticipated during 1H 2023 – – Presented preclinical data showing
- 4y agoCDAKCodiak Presents Preclinical Data Demonstrating its Pan Beta-Coronavirus Vaccine Elicits Broad Protective Immunity Against Known Variants of SARS-CoV-2 and Related SarbecovirusesGlobeNewswire– Data support advancement of Codiak's engineered exosome bivalent vaccine candidate toward IND-enabling studies – CAMBRIDGE, Mass., Oct. 12, 2022 (GLOBE NEWSWIRE) -- Codiak BioSciences, Inc. (NASDAQ:CDAK), a
- 4y agoCDAKCodiak to Present New Preclinical Data Demonstrating Potent Monotherapy Activity of Two Engineered Exosome Intravenous Candidates Targeting MacrophagesGlobeNewswire– Data to be presented at the Society for Immunotherapy of Cancer (SITC) Annual Meeting – CAMBRIDGE, Mass., Oct. 05, 2022 (GLOBE NEWSWIRE) -- Codiak BioSciences, Inc. (NASDAQ:CDAK), a clinical-stage biopharmaceutical company focused on pioneerin
- 4y agoCDAKCodiak Announces Pricing of $20 Million Public Offering of Common Stock and WarrantsGlobeNewswireCAMBRIDGE, Mass., Sept. 12, 2022 (GLOBE NEWSWIRE) -- Codiak BioSciences, Inc. (NASDAQ:CDAK) ("Codiak"), a clinical-stage biopharmaceutical company pioneering the development of exosome-based therapeutics as a new class of medicines, announced today the
- 4y agoCDAKCodiak Announces Proposed Public Offering of Common Stock and WarrantsGlobeNewswireCAMBRIDGE, Mass., Sept. 12, 2022 (GLOBE NEWSWIRE) -- Codiak BioSciences, Inc. (NASDAQ:CDAK) ("Codiak"), a clinical-stage biopharmaceutical company pioneering the development of exosome-based therapeutics as a new class of medicines, announced today tha
- 4y agoCDAKCodiak BioSciences Announces Program Reprioritization and Corporate RestructuringGlobeNewswire– Enrollment continues in Phase 1 clinical trial of IV-administered exoASO™-STAT6 in patients with advanced hepatocellular carcinoma – – Prioritizing vaccine program funded by CEPI and advancement of engEx-A
- 4y agoCDAKCodiak BioSciences Reports Second Quarter 2022 Financial Results and Operational ProgressGlobeNewswire– Reported platform-validating initial data from Phase 1 studies of exoSTING™ and exoIL-12™; plans to initiate Phase 2 studies for both programs in 1H 2023 – – Initiated patient dosing in Phase 1 clinical trial of exoASO™-STAT6 in patien
- 4y agoCDAKCodiak BioSciences to Participate in Upcoming BTIG and Wedbush PacGrow Investor ConferencesGlobeNewswireCAMBRIDGE, Mass., Aug. 03, 2022 (GLOBE NEWSWIRE) -- Codiak BioSciences, Inc. (NASDAQ:CDAK), a clinical-stage biopharmaceutical company pioneering the development of exosome-based therapeutics as a new class of medicines, today announced that management
- 4y agoCDAKCodiak BioSciences to Participate at William Blair Biotech Focus Conference 2022GlobeNewswireCAMBRIDGE, Mass., July 11, 2022 (GLOBE NEWSWIRE) -- Codiak BioSciences, Inc. (NASDAQ:CDAK), a clinical-stage biopharmaceutical company pioneering the development of exosome-based therapeutics as a new class of medicines, today announced that management
- 4y agoCDAKCEPI and Codiak BioSciences partner to develop broadly protective Betacoronavirus vaccineGlobeNewswireOSLO, Norway and CAMBRIDGE, Mass., July 05, 2022 (GLOBE NEWSWIRE) -- CEPI, the Coalition for Epidemic Preparedness Innovations, and Codiak BioSciences (NASDAQ:CDAK) today announced the latest funding award under CEPI's US $200m programme to advance t
- 4y agoCDAKCodiak Provides Platform-Validating Clinical Update and Data from Phase 1 Trials of exoSTING™ and exoIL-12™GlobeNewswire– Codiak's engineered exosome candidates demonstrate potential for best-in-class profile, with tumor retention and delivery to the cells of interest allowing for increased therapeutic window – – exoSTING and exoIL-12 demonstrated favorable safet
- 4y agoCDAKCodiak Initiates Patient Dosing in Phase 1 Clinical Trial of exoASO™-STAT6 in Patients with Advanced Hepatocellular Carcinoma, Liver Metastases from Primary Gastric Cancer and Colorectal CancerGlobeNewswireexoASO-STAT6 is the third engineered exosome candidate generated from Codiak's engEx® Platform to enter clinical development CAMBRIDGE, Mass., June 29, 2022 (GLOBE NEWSWIRE) -- Codiak BioSciences, Inc. (NASDAQ:CDAK), a clinical-stage biopharmaceu
- 4y agoCDAKCodiak Presents New Preclinical Data at ASGCT 2022 on Exosome-Based Strategy to Enhance AAV Gene TherapyGlobeNewswireCAMBRIDGE, Mass., May 17, 2022 (GLOBE NEWSWIRE) -- Codiak BioSciences, Inc. (NASDAQ:CDAK), a clinical-stage biopharmaceutical company pioneering the development of exosome-based therapeutics as a new class of medicines, today announced new preclinical
- 4y agoCDAKCodiak BioSciences Reports First Quarter 2022 Financial Results and Operational ProgressGlobeNewswire– Codiak to provide data from ongoing exoSTING™ and exoIL-12™ clinical trials in late 1H 2022 – – Anticipate first patients dosed in exoASO™-STAT6 Phase 1 clinical trial in 1H 2022 – – Data from preclinical engEx-AAV™ program to b
- 4y agoCDAKCodiak Appoints David Mauro, M.D., Ph.D., as Chief Medical OfficerGlobeNewswireCAMBRIDGE, Mass., May 02, 2022 (GLOBE NEWSWIRE) -- Codiak BioSciences, Inc. (NASDAQ:CDAK), a clinical-stage biopharmaceutical company pioneering the development of exosome-based therapeutics as a new class of medicines, today announced the appointment
- 4y agoCDAKCodiak Presents New Preclinical Data Supporting Development of a Broadly Protective Pan Beta-Coronavirus VaccineGlobeNewswire– Engineered exosome vaccine construct generated durable, comprehensive immunity in vivo – CAMBRIDGE, Mass., April 20, 2022 (GLOBE NEWSWIRE) -- Codiak BioSciences, Inc. (NASDAQ:CDAK), a clinical-stage biopharmaceutical company focused on pioneer
- 4y agoAXLACDAKDNLIEVLO+7Tessera Therapeutics Announces Over $300M Series C Financing to Advance its GENE WRITING PlatformBusiness WireLatest Financing Round Will Support Tessera's Build Out of its GENE WRITING Platforms and Pursuit of Multiple Therapeutic Programs for Clinical Development Tessera Therapeutics, the biotechnology company pioneering a new approach in genetic medicine
- 4y agoAXLACDAKDNLIEVLO+7Flagship Pioneering Bolsters Executive Team with Appointment of Michelle C. Werner as CEO-Partner and CEO of AlltrnaPR NewswireWerner Brings More Than Two Decades of Pharmaceutical Leadership to the Role CAMBRIDGE, Mass., April 11, 2022 /PRNewswire/ -- Flagship Pioneering, the bioplatform innovation company, today announced it has strengthened its executive leadership team w
- 4y agoCDAKCodiak's exoASO™-C/EBPβ Demonstrates Significant Systemic Anti-Tumor Activity via Targeting Immune-Suppressive Myeloid CellsGlobeNewswire– New preclinical data presented at AACR Annual Meeting 2022 – – Intravenous exosome candidate engineered for tropism precisely targets transcription factors in myeloid cell subpopulations – – Precision medicine approach enables poten
- 4y agoCDAKCodiak BioSciences Reports Fourth Quarter and Full Year 2021 Financial Results and Recent Operational ProgressGlobeNewswire– Reported positive initial data from exoSTING™ clinical trial; on track to provide data from all dose escalation cohorts in late 1H 2022 – – Investigational New Drug (IND) application cleared for exoASO™-STAT6, with clinical trial initiatio
- 4y agoAXLACDAKDNLIEVLO+8Alltrna Appoints Rare Disease Clinical Research Expert, Dr. Anne Pariser, as Vice President, Medical and Regulatory AffairsPR NewswireCAMBRIDGE, Mass., Feb. 28, 2022 /PRNewswire/ -- Alltrna, a Flagship Pioneering company unlocking transfer RNA (tRNA) biology and pioneering tRNA therapeutics to regulate the protein universe and resolve disease, today announced the appointment of Anne Pa
- 4y agoCDAKData from Codiak's exoASO™-STAT6 Preclinical Development Program for the Treatment of Primary and Metastatic Hepatic Cancers Published in Science AdvancesGlobeNewswire– Unprecedented monotherapy activity via macrophage reprogramming in preclinical models – – Phase 1 study expected to begin in 1H 2022 – CAMBRIDGE, Mass., Feb. 18, 2022 (GLOBE NEWSWIRE) -- Codiak BioSciences, Inc. (NASDAQ:CDAK), a clinica
- 4y agoAXLACDAKDNLIEVLO+7INVAIO SCIENCES STRENGTHENS ITS BOARD OF DIRECTORS WITH THE APPOINTMENT OF HUGH GRANTPR NewswireCAMBRIDGE, Mass., Feb. 15, 2022 /PRNewswire/ -- Invaio Sciences, Inc., a Flagship Pioneering company focused on unlocking the potential of the planet's interdependent natural systems to solve pressing agricultural, sustainability, and environmental chall
- 4y agoAXLACDAKDNLIEVLO+8Cellarity Expands Leadership Team to Continue Evolution of a Breakthrough Platform to Encode Biology and Purposefully Create New MedicinesBusiness WireCompany increases industry expertise with the appointments of Laurens Kruidenier, Ph.D., as Chief Scientific Officer; Anna O'Driscoll as Chief People Officer, and Parul Doshi as Senior Vice President, Head of Data and Software Engineering Cellarity,
- 4y agoAXLACDAKDNLIEVLO+8Senda Biosciences Appoints Stuart Milstein, Ph.D., as SVP and Head of Platform BiologyPR NewswireCAMBRIDGE, Mass., Jan. 26, 2022 /PRNewswire/ -- Senda Biosciences, Inc., a company that is harnessing nature to program targeted, potent and tunable medicines, has appointed Stuart Milstein, Ph.D., to the newly created position of Senior Vice President
- 4y agoAXLACDAKDNLIEVLO+8Flagship Pioneering Announces Appointment of Tom DiLenge as Senior Partner, Global Public Policy, Regulatory & Governmental StrategyPR NewswireCAMBRIDGE, Mass., Jan. 25, 2022 /PRNewswire/ -- Flagship Pioneering, the bioplatform innovation company, announced today that Tom DiLenge has joined the company in a newly created role as Senior Partner, Global Public Policy, Regulatory & Governmental St
- 4y agoCDAKXFORSporos Bioventures Announces Formation of Strategic Advisory BoardBusiness WireDr. Doug Williams to Chair SAB Inaugural members include Drs. Keith Flaherty, Bing Yao, and Doug Hanahan to advise on company's growing pipeline and discovery engine Sporos Bioventures, LLC, ("Sporos" or the "Company") a private biotechnology comp
- 4y agoCDAKCodiak BioSciences to Present at the H.C. Wainwright Virtual BioConnect 2022 ConferenceGlobeNewswireCAMBRIDGE, Mass., Jan. 06, 2022 (GLOBE NEWSWIRE) -- Codiak BioSciences, Inc. (NASDAQ:CDAK), a clinical-stage biopharmaceutical company pioneering the development of exosome-based therapeutics as a new class of medicines, today announced that Douglas E.
- 4y agoAXLACDAKDNLIEVLO+9Cellarity Appoints Biopharmaceutical Executive Ian Estepan to its Board of DirectorsBusiness WireEstepan brings to Cellarity's BOD deep experience and expertise in all aspects of finance, corporate strategy, investor relations, and business development, and a dedication to directly improving patient lives through innovation in medicine Cellarity
- 4y agoCDAKCodiak's Engineered Exosomes Promote T Cell and Antibody Responses to SARS-CoV-2 in vivo, Supporting the Potential for a Broadly Protective Pan-Beta Coronavirus and Variant VaccineGlobeNewswireCAMBRIDGE, Mass., Dec. 02, 2021 (GLOBE NEWSWIRE) -- Codiak BioSciences, Inc. (NASDAQ:CDAK), a clinical-stage biopharmaceutical company focused on pioneering the development of exosome-based therapeutics as a new class of medicines, today announced new
- 4y agoCDAKCodiak BioSciences to Present at the 4th Annual Evercore ISI HealthCONx ConferenceGlobeNewswireCAMBRIDGE, Mass., Dec. 01, 2021 (GLOBE NEWSWIRE) -- Codiak BioSciences, Inc. (NASDAQ:CDAK), a clinical-stage biopharmaceutical company pioneering the development of exosome-based therapeutics as a new class of medicines, today announced that Douglas E.
- 4y agoCDAKCodiak BioSciences Announces FDA Clearance of IND for exoASO™-STAT6; Patient Dosing Expected 1H 2022GlobeNewswire– Codiak's first engineered exosome therapeutic candidate for systemic administration – – Single agent anti-tumor effect observed in preclinical models via macrophage reprogramming – – Phase 1 trial will evaluate safety, tolerability,
- 4y agoAXLACDAKDNLIEVLO+8Generate Biomedicines Announces First External Equity Raise of $370 Million to Advance Its Drug Generation PlatformBusiness Wire- Generate is harnessing the power of data and machine learning at scale to program biology, dramatically improve the human condition, and democratize biotherapeutics - New capital will enable the company to evolve its technology platform, rapidly sc
- 4y agoCDAKCodiak Reports Positive Initial Data for exoSTING™ Phase 1/2 Trial Indicating Tolerability, Immune Activation, and Evidence of Tumor Shrinkage in Injected and Non-Injected Tumors in the First Three Dose Escalation CohortsGlobeNewswire– exoSTING resulted in localized STING pathway activation and dose-dependent immune activation – – Intratumoral administration of exoSTING was well tolerated and demonstrated tumor retention, no systemic exposure to STING agonist, and in a subse
- 4y agoAXLACDAKDNLIEVLO+8Flagship Pioneering Announces Appointment of Justine Levin-Allerhand as Senior Partner, Corporate DevelopmentPR NewswireCAMBRIDGE, Mass., Nov. 15, 2021 /PRNewswire/ -- Flagship Pioneering, the bioplatform innovation company, announced today that Justine Levin-Allerhand, Ph.D., has joined the company in a newly created role as Senior Partner, Corporate Development. In this
- 5y agoCDAKNew Preclinical Data at SITC 2021 Show Broad Potential Utility of Codiak's Engineered ExosomesGlobeNewswire– exoSTING™ monotherapy suppressed tumor growth and improved overall survival in a preclinical model of leptomeningeal disease, an aggressive metastasis of cancer to the central nervous system – – Combination of exoSTING™ and exoIL-12™ gen
- 5y agoCDAKCodiak BioSciences Reports Third Quarter 2021 Financial Results and Recent Operational ProgressGlobeNewswire– Announced strategic long-term exosome manufacturing collaboration with Lonza – – Initial data readout from exoSTING™ clinical trial expected in Q4 2021; initial data from exoIL-12™ trial in CTCL patients now anticipated in H1 2022 –
- 5y agoAXLACDAKDNLIEVLO+8Tessera Therapeutics Announces R&D Collaboration with Cystic Fibrosis Foundation as Part of a Portfolio of Complementary Technologies Advanced by Flagship's Pioneering Medicines to Treat Cystic FibrosisBusiness WireTessera's Gene WritingTM Technology is Designed to Simultaneously Correct Multiple Genetic Mutations as well as to Write Genes in Their Entirety Tessera Therapeutics today announced a treatment-focused collaboration with the Cystic Fibrosis Foundatio
- 5y agoCDAKLonza to Acquire Codiak BioSciences Exosomes Manufacturing Facility and Establish a Long-Term Strategic CollaborationGlobeNewswireLonza to acquire and operate Codiak's Lexington, MA (US) facility and become the strategic manufacturing partner for Codiak's pipeline Lonza and Codiak to establish a Center of Excellence focused on exosome manufacturing and characterization technologi
- 5y agoAXLACDAKDNLIEVLO+7Invaio Sciences Secures $50 Million Debt Financing to Develop and Commercialize Agricultural Solutions to Address Climate ChangePR NewswireCAMBRIDGE, Mass., Oct. 13, 2021 /PRNewswire/ -- Invaio Sciences, Inc., a Flagship Pioneering company unlocking the potential of natural systems to accelerate the transition to sustainable agriculture to urgently address climate change, has entered into
- 5y agoCDAKCodiak to Present Preclinical Data Demonstrating New Potential Therapeutic Applications of Engineered Exosomes at the Society for Immunotherapy of Cancer (SITC) Annual MeetingGlobeNewswireCAMBRIDGE, Mass., Oct. 01, 2021 (GLOBE NEWSWIRE) -- Codiak BioSciences, Inc. (NASDAQ:CDAK), a clinical-stage biopharmaceutical company focused on pioneering the development of exosome-based therapeutics as a new class of medicines, today announced that
- 5y agoCDAKCodiak BioSciences Appoints Lini Pandite, MBChB, MBA to Board of DirectorsGlobeNewswireCAMBRIDGE, Mass., Aug. 18, 2021 (GLOBE NEWSWIRE) -- Codiak BioSciences, Inc. (NASDAQ:CDAK), a clinical-stage biopharmaceutical company focused on pioneering the development of exosome-based therapeutics as a new class of medicines, announced today it h
- 5y agoCDAKCodiak BioSciences Reports Second Quarter 2021 Financial Results and Operational ProgressGlobeNewswire– Initial safety and PK/PD data from Phase 1/2 study of exoSTING™ now expected in the fourth quarter of 2021 – – Initial safety and efficacy data from Phase 1 trial of exoIL-12™ in CTCL anticipated by year-end – ��
- 5y agoCDAKCodiak BioSciences to Present at the Virtual William Blair Biotech Focus Conference 2021GlobeNewswireCAMBRIDGE, Mass., July 07, 2021 (GLOBE NEWSWIRE) -- Codiak BioSciences, Inc. (NASDAQ:CDAK), a clinical-stage biopharmaceutical company focused on pioneering the development of exosome-based therapeutics as a new class of medicines, today announced that
- 5y agoCDAKCodiak BioSciences Announces the Transition of Benny Sorensen, M.D., Ph.D. to Scientific Advisory Board Member and Clinical Consultant RolesGlobeNewswireCAMBRIDGE, Mass., July 06, 2021 (GLOBE NEWSWIRE) -- Codiak BioSciences, Inc. (NASDAQ:CDAK), a clinical-stage biopharmaceutical company focused on pioneering the development of exosome-based therapeutics as a new class of medicines, today announced that
- 5y agoAXLACDAKDNLIEVLO+7Tessera Therapeutics Appoints Industry Leaders Elliott Sigal & Mary Rozenman to Board of DirectorsBusiness WireNew Board Members Will Help Advance ‘Gene Writing' Platform and Mission to Cure Disease by Writing in the Code of Life Tessera Therapeutics, a biotech company pioneering Gene Writing, announced today the appointment of Elliott Sigal, M.D., Ph.D. an
- 5y agoAXLACDAKDNLIEVLO+7Flagship Pioneering Closes $3.4 Billion Capital Pool to Drive Continued Breakthrough Innovations in Human Health and SustainabilityPR NewswireCAMBRIDGE, Mass., June 14, 2021 /PRNewswire/ -- Flagship Pioneering, the bioplatform innovation company, today announced a significant expansion of its capital base to support founding and growing its next generation of human health and sustainability c